Sponsor:
Revolution Medicines, Inc.
Code:
NCT06445062
Conditions
Colorectal Cancer
CRC
Pancreatic Ductal Adenocarcinoma
PDAC
Gastrointestinal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RMC-6236
mFOLFOX6 regimen
bevacizumab
mFOLFIRINOX regimen
cetuximab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations